Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1Since this was a Phase 1 trial focused on how children's bodies absorb and process fluticasone propionate and albuterol together, what did the results tell us about whether the drug levels in kids aged 4 to 11 look safe compared to using fluticasone alone?
2. 2This trial is now completed — does that mean the findings are published or available, and could the results change how you'd think about using a combination fluticasone and albuterol dry powder inhaler for my child's asthma?
3. 3Because this was a pharmacokinetic study measuring things like drug concentration peaks and how long the medications stay in the body, does it tell us anything about whether the combination inhaler actually controls asthma better, or is that still unknown?
4. 4Given that my child would be in the 4-to-11 age group this trial studied, are there any safety signals from the blood concentration data — like unexpectedly high peaks or slow clearance of either drug — that you'd want to factor into their current treatment plan?
5. 5Are there standard approved treatments for my child's asthma that we should consider first, or do the results from this kind of early-phase study suggest the combination inhaler might be worth pursuing through newer or ongoing trials?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.